文献速递药物相互作用治疗药物监测与药物基因组学特殊人群用药

SCN2A癫痫婴儿卡马西平、苯妥英与生酮饮食的相互作用

Drug-drug and drug-food interactions in an infant with early-onset SCN2A epilepsy treated with carbamazepine, phenytoin and a ketogenic diet.
PubMed 文献 · Br J Clin Pharmacol · 2020-08-13

本文报道一名早发型SCN2A癫痫婴儿,从大剂量苯妥英(20 mg/kg/d,浓度≥20 mg/L)联合生酮饮食转换为卡马西平(50-75 mg/kg/d,浓度9-12 mg/L)历时85天,模型分析显示苯妥英介导CYP3A4诱导和卡马西平自身诱导使表观清除率增加至2.5/3倍,生酮饮食下卡马西平相对生物利用度降至44%。提示生酮饮食引入或去除时需监测卡马西平浓度,尤其联用大剂量苯妥英的婴儿需高剂量卡马西平才能达标。

要点

  • 苯妥英通过CYP3A4诱导及卡马西平自身诱导可使其表观清除率增加至2.5/3倍。
  • 生酮饮食下卡马西平相对生物利用度降至44%,需监测浓度。
  • 生酮饮食引入或去除时及联用大剂量苯妥英的婴儿应密切监测卡马西平浓度。

核心结论

  • 苯妥英介导的CYP3A4诱导和卡马西平自身诱导显著增加卡马西平清除,生酮饮食降低其相对生物利用度至44%,导致转换期间卡马西平浓度不足。

研究设计与样本

  • 单例婴儿病例报告,结合卡马西平药代动力学模型分析。

主要发现

  • 从大剂量苯妥英(20 mg/kg/d,浓度≥20 mg/L)联合生酮饮食转换为卡马西平(50-75 mg/kg/d,浓度9-12 mg/L)历时85天。
  • 模型分析显示苯妥英介导的CYP3A4诱导和卡马西平自身诱导呈时间和剂量依赖性,表观清除率增加至2.5/3倍。
  • 生酮饮食下卡马西平浓度较低,模型拟合为相对生物利用度降至44%。

临床怎么用

  • 生酮饮食引入或去除时以及联用大剂量苯妥英的婴儿,应监测卡马西平浓度。
  • 联用大剂量苯妥英时可能需要高剂量卡马西平才能达到治疗浓度。

局限性

  • 为单例病例报告,药代动力学模型分析结果需在更多患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium channel 2 subunit α (SCN2A) mutations cause difficult-to-treat early-onset epilepsy. Effective treatment includes high-dose phenytoin or carbamazepine ± ketogenic diet (KD). We describe an infant with early-onset SCN2A-epilepsy with subtherapeutic carbamazepine concentration during transition from phenytoin treatment to avoid long-term neurotoxicity. The transition from high-dose phenytoin (20 mg kg-1 d-1 , concentration: ≥20 mg/L) with KD, to carbamazepine (50-75 mg kg-1 d-1 , concentration: 9-12 mg/L) lasted 85 days, which we suspected was due to significant drug-drug and/or drug-food interactions. Model-based analysis of carbamazepine pharmacokinetics quantified significant time- and dose-dependent phenytoin-mediated CYP3A4 induction and carbamazepine concentration-dependent auto-induction (apparent clearance increased up to 2.5/3-fold). Lower carbamazepine concentrations under KD were modelled as decreased relative bioavailability (44%), potentially related to decreased fraction absorbed (unexpected for this lipophilic drug), increased intestinal/hepatic metabolism and/or decreased protein-binding with KD. This suggests importance of carbamazepine-concentration monitoring during KD-introduction/removal and necessity of high carbamazepine doses to achieve therapeutic concentrations, especially in infants treated with high-dose phenytoin.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Welzel T, Ziesenitz VC, Weber P, et al. Drug-drug and drug-food interactions in an infant with early-onset SCN2A epilepsy treated with carbamazepine, phenytoin and a ketogenic diet. Br J Clin Pharmacol. 2020. PMID: 32737897. doi:10.1111/bcp.14503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。